Rituximab (Rituxan)

American Journal of Neuroradiology

Volumn 31, Issue 7, 2010, Pages 1178-1180

  Selewski, David T ^a   Shah, G V ^b   Mody, R J ^a   Rajdev, P A ^c   Mukherji, S K ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; RITUXIMAB; VINCRISTINE;

ANGIONEUROTIC EDEMA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LYMPHOMA; BRAIN EDEMA; BRONCHOSPASM; CHICKENPOX; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOMEGALOVIRUS INFECTION; DRUG COST; DRUG ERUPTION; DRUG FEVER; DRUG INDICATION; DRUG MECHANISM; ERYTHEMA INFECTIOSUM; GRAFT VERSUS HOST REACTION; HEPATITIS B; HERPES SIMPLEX; HUMAN; HYPOTENSION; LYMPHOPROLIFERATIVE DISEASE; MUCOCUTANEOUS REACTION; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PEMPHIGUS VULGARIS; PNEUMOCYSTIS PNEUMONIA; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISORDER; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; URTICARIA;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; FEMALE; HUMANS; LYMPHOMA, B-CELL;

EID: 77955632562     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A2142     Document Type: Review

References (15)

1. Avivi I, Robinson S, Goldstone A. Clinical use of rituximab in haematological malignancies. Br J Cancer 2003;89:1389-94 (Pubitemid 37390853)
2. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four dose treatment program. J Clin Oncol 1998;16:2825-33
3. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23. Epub 2004 Oct 19
4. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42
5. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81 (Pubitemid 38758544)
6. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45 (Pubitemid 24030569)
7. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-66
8. Pesocovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006;6:859-66
9. Ng CM, Bruno R, Combs D, et al. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis during a phase II clinical trial. J Clin Pharmacol 2005;45:792-801 (Pubitemid 40875331)
10. Adeli MM, Eichner B, Thornburg C, et al. Persistent antibody depletion after rituximab in three children with autoimmune cytopenias. Pediatr Hematol Oncol 2009;26:566-72
11. Quartier P, Brethon B, Philippet P, et al.Atreatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001;358:1511-13 (Pubitemid 33055705)
12. Rituxan [package insert]. South San Francisco, California: Biogen-IDEC/Genentech; 2008
13. Carson K, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol 2009;10:816-24
14. Shelton E, Yong M, Cohney S. Late onset pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology 2009;14:696-99
15. Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002;99:1486-88